Intra-Articular Dexmedetomidine: A Treatment for Chronic Knee Pain
ConditionChronic Knee Pain
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40-75
SponsorTanta University
About this trial
Chronic knee osteoarthritis (KOA) is a painful condition with limited treatment options. Non-pharmacological approaches often fall short, leading to decreased quality of life. Ozone therapy, a simple and affordable treatment, has shown promise for pain relief. Dexmedetomidine (DEX), a sedative and analgesic, has been used successfully as an adjuvant to anesthesia and local anesthetics. Given its potential for pain management, exploring DEX as a treatment for KOA could offer a new and promising approach.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients were not assigned for surgical intervention;
Patients were free of
Disqualifiers
Patients were assigned for surgical intervention;
Patients who had uncontrolled hypertension and/or diabetes mellitus;
Patients who had uncompensated cardiac, renal, or hepatic diseases;
Patients with coagulopathy, spinal deformity, allergy, or contraindication for the used drugs;
Trial design
Design model
Parallel
Treatments tested in this trial
Triamcinolone Acetonide
Drug1 ml of triamcinolone acetonide was used to prepare a solution for knee injection for patients with Chronic Knee Pain
Bupivacaine Hydrochloride
Drug20mg of bupivacaine hydrochloride was used to prepare a solution for knee injection for patients with Chronic Knee Pain
Dexmedetomidine
DrugDexmedetomidine solution was prepared by mixing Dexmedetomidine in a dose of 3 µg/kg in 5-ml saline
Treatment groups
70 Participants
are divided into 2 treatment groupsGroup A: Group 1Active comparator 2 interventions
Group B: Group 2Active comparator 1 intervention
Trial outcomes
Primary outcomes
1
Proportion of patients reporting at least a 50% reduction in pain (measured by Numerical Rating Scale) post-intra-articular Injection.
Value of intra-articular Injection in Pain Reduction of chronic knee pain manifested by recurrence of pain.
Time frame
7 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov